Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.00% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
RKDA · Sep 30, 2024
Arcadia Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-24-125613General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-113.99% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-3.76% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
54.33% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
32.86% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-114.51% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
1.56% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
10.08% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History19 statesSelf-history eligible
Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/8 normalizedLevel 3Dec 31, 20220/8 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20230/8 normalizedLevel 3Sep 30, 20236/8 normalizedLevel 3Dec 31, 20237/8 normalizedLevel 3Mar 31, 20247/8 normalizedLevel 3Jun 30, 20247/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 0.23%
- Current
- 0.00%
- Delta
- -0.23%
- Previous
- -188.06%
- Current
- -113.99%
- Delta
- 74.07%
- Previous
- -5.98%
- Current
- -3.76%
- Delta
- 2.22%
- Previous
- 74.89%
- Current
- 54.33%
- Delta
- -20.56%
- Previous
- 51.53%
- Current
- 32.86%
- Delta
- -18.68%
- Previous
- 151.61%
- Current
- -114.51%
- Delta
- -266.12%
- Previous
- 0.77%
- Current
- 1.56%
- Delta
- 0.80%
- Previous
- 7.81%
- Current
- 10.08%
- Delta
- 2.27%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · RKDA Fundamental State →Analogous To · RKDA state analogue 3 →Has State · Arcadia Biosciences, Inc. →Transitioned To · RKDA Fundamental State →Transitioned To · RKDA CAPEX_INTENSITY_DECREASED →Transitioned To · RKDA CASH_GENERATION_INCREASED →Transitioned To · RKDA GROWTH_INCREASED →Transitioned To · RKDA INVENTORY_PRESSURE_DECREASED →Transitioned To · RKDA MARGIN_DECREASED →Transitioned To · RKDA PROFITABILITY_DECREASED →Transitioned To · RKDA R_AND_D_INTENSITY_INCREASED →Transitioned To · RKDA SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.